Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | GART | P22102 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588170 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL14167625 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049826 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL29518246 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049828 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL4407799 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL13753507 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049830 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL14167660 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049823 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402811-B1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK AS (DK) | 2022-03-30 | — | — | EP | claimed |
| CN-117677628-A | GHR binding pending peptides and compositions comprising the same | 肽梦想株式会社 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023012263-A1 | SOLID ORAL PEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2023-02-09 | — | — | WO | disclosed |
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2023-01-05 | — | — | US | disclosed |
| US-20220323544-A1 | SOLID COMPOSITIONS COMPRISING AN EGF(A) DERIVATIVE AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK A/S (DK) | 2022-10-13 | — | — | US | disclosed |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | SAINT LOUIS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3402811-B1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK AS (DK) | 2022-03-30 | — | — | EP | disclosed |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| WO-2019023295-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | PCSK9, EGFR, PCSK6 | NOD1 2285/4885FOLH1 802/4885RIMKLA 1286/4885 |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | FABP2, FGFR2, FGF2 | NOD1 4150/4885FOLH1 1264/4885RIMKLA 1660/4885 |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | FABP2, EGFR, HGF | NOD1 4643/4885FOLH1 581/4885RIMKLA 2533/4885 |
| US-20220323544-A1 | SOLID COMPOSITIONS COMPRISING AN EGF(A) DERIVATIVE AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | PCSK9, EGFR, PCSK6 | NOD1 2650/4885FOLH1 543/4885RIMKLA 1460/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | NOD1 3835/4885FOLH1 524/4885RIMKLA 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.